Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ralph Corey
Martin E Stryjewski

Showing results (81-90 of 194) with videos related to

Pageof 20
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2005
A returning traveler with fever and rashDeverick J Anderson, William Fangman, Vance G Fowler, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2018
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO StudiesG Ralph Corey, Jeffery Loutit, Greg Moeck, et al.
Antimicrobial Agents and Chemotherapy|February 28, 2024
Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimensJürgen B Bulitta, Edward Fang, Martin E Stryjewski, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 2010
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infectionsMark H Wilcox, G Ralph Corey, George H Talbot, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 2010
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infectionsG Ralph Corey, Mark H Wilcox, George H Talbot, et al.
The Journal of Antimicrobial Chemotherapy|June 11, 2013
A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumoniaPaul S Covington, J Michael Davenport, David A Andrae, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 4, 2008
Emergence of coagulase-negative staphylococci as a cause of native valve endocarditisVivian H Chu, Christopher W Woods, Jose M Miro, et al.
Diagnostic Microbiology and Infectious Disease|January 8, 2018
Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and EuropeDavid B Huang, Thomas M File, Matthew Dryden, et al.
The Lancet. Infectious Diseases|June 10, 2014
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trialGregory J Moran, Edward Fang, G Ralph Corey, et al.
Journal of Medical Microbiology|September 16, 2003
Fatal outcome of bacteraemic patients caused by infection with staphylokinase-deficient Staphylococcus aureus strainsTao Jin, Maria Bokarewa, Lauren McIntyre, et al.
Pageof 20

Showing results (81-90 of 194) with videos related to

Sort By:
Pageof 20
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2005
A returning traveler with fever and rashDeverick J Anderson, William Fangman, Vance G Fowler, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2018
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO StudiesG Ralph Corey, Jeffery Loutit, Greg Moeck, et al.
Antimicrobial Agents and Chemotherapy|February 28, 2024
Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimensJürgen B Bulitta, Edward Fang, Martin E Stryjewski, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 2010
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infectionsMark H Wilcox, G Ralph Corey, George H Talbot, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 2010
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infectionsG Ralph Corey, Mark H Wilcox, George H Talbot, et al.
The Journal of Antimicrobial Chemotherapy|June 11, 2013
A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumoniaPaul S Covington, J Michael Davenport, David A Andrae, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 4, 2008
Emergence of coagulase-negative staphylococci as a cause of native valve endocarditisVivian H Chu, Christopher W Woods, Jose M Miro, et al.
Diagnostic Microbiology and Infectious Disease|January 8, 2018
Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and EuropeDavid B Huang, Thomas M File, Matthew Dryden, et al.
The Lancet. Infectious Diseases|June 10, 2014
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trialGregory J Moran, Edward Fang, G Ralph Corey, et al.
Journal of Medical Microbiology|September 16, 2003
Fatal outcome of bacteraemic patients caused by infection with staphylokinase-deficient Staphylococcus aureus strainsTao Jin, Maria Bokarewa, Lauren McIntyre, et al.
Pageof 20